CRISPR Therapeutics AG stock is trading -31.32% below its average target price of $84.63 after dropping -3.6% during today's evening session. Analysts are giving the mid-cap Biotechnology company an average rating of buy and target prices ranging from $30.0 to $188.0 per share.
The stock has an unusually large proportion of its shares sold short at 20.3%, and a short ratio of 5.3. Since 1.4% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 66.9% of CRISPR Therapeutics AG's shares being owned by this investor type.
Institutions Invested in CRISPR Therapeutics AG
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | ARK Investment Management, LLC | 9% | 7,163,118 | $416,320,410 |
| 2023-09-30 | Capital International Investors | 8% | 6,085,512 | $353,689,950 |
| 2023-09-30 | T. Rowe Price Investment Management, Inc. | 5% | 3,651,833 | $212,244,530 |
| 2023-09-30 | Sumitomo Mitsui Trust Holdings, Inc. | 4% | 3,465,470 | $201,413,112 |
| 2023-09-30 | Nikko Asset Management Americas, Inc. | 4% | 3,465,470 | $201,413,112 |
| 2023-09-30 | Blackrock Inc. | 3% | 2,713,210 | $157,691,762 |
| 2023-09-30 | FMR, LLC | 3% | 2,057,414 | $119,576,899 |
| 2023-09-30 | State Street Corporation | 2% | 1,884,973 | $109,554,628 |
| 2023-09-30 | NEA Management Company, LLC | 2% | 1,587,854 | $92,286,072 |
| 2023-09-30 | Vanguard Group Inc | 2% | 1,538,725 | $89,430,695 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on CRISPR Therapeutics AG.
